A Study of LY4064809 in Healthy Adult Participants

Inclusion criteria

• Are healthy as determined by medical evaluation, including medical history, physical examination, vital signs, and electrocardiogram (ECG) at screening and admission.
• Have clinical laboratory test results within the normal range
• Have normal blood pressure and pulse rate or not clinically significant
• Have a BMI within the range 18 to 32 kg/m2
• Participants assigned male at birth or assigned female at birth who are not of childbearing potential

Exclusion criteria

• History or presence of any of the following conditions, deemed clinically significant by the investigator (or designee):

• metabolic disease, including congenital non-hemolytic hyperbilirubinemia, for example, Gilbert syndrome
• bile duct disease, including removal of the gall bladder
• digestive system disease
• blood disease
• disease of the nervous system
• significant history of, or presence of, liver disease, including any abnormal liver function tests
• heart disease
• Have an abnormal electrocardiogram (ECG) at screening or admission
• History of a major surgical procedure within 30 days prior to screening
• Diagnosed or treated cancer within 5 years prior to screening, with the exception of the following cancers cured through treatment: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and in situ carcinoma of the cervix cured through surgery

• Clinically significant history of multiple or severe drug hypersensitivity reactions or drug allergies, as determined by the investigator
• Have used or plan to use medication within 14 days prior to admission, or plan to use during the study with the exception of acetaminophen
• Have creatinine lab clearance less than 90mL/min calculated using the Cockroft-Gault equation at screening
• Have a positive Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody or human immunodeficiency virus 1 and 2 antibody results at the screening visit